Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. Summary
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
53.12(c) 53.47(c) 53.21(c) 53.61(c) 53.26(c) Last
2 046 017 1 967 469 1 776 133 1 703 725 2 277 694 Volume
+0.21% +0.66% -0.49% +0.75% -0.65% Change
More quotes
Financials
Sales 2021 41 349 M 49 575 M 49 575 M
Net income 2021 3 593 M 4 308 M 4 308 M
Net Debt 2021 38 658 M 46 349 M 46 349 M
P/E ratio 2021 15,6x
Yield 2021 3,80%
Sales 2022 42 821 M 51 340 M 51 340 M
Net income 2022 4 478 M 5 368 M 5 368 M
Net Debt 2022 36 696 M 43 996 M 43 996 M
P/E ratio 2022 12,3x
Yield 2022 4,06%
Capitalization 52 324 M 63 408 M 62 734 M
EV / Sales 2021 2,20x
EV / Sales 2022 2,08x
Nbr of Employees 99 329
Free-Float 100,0%
More Financials
Company
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (45.5%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (41.7%) : intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc. ; - OTC... 
Sector
Pharmaceuticals
Calendar
08/05Earnings Release
More about the company
Ratings of Bayer AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about BAYER AG
05:07pCureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy
RE
04:43pPRESS RELEASE  : CureVac Provides Update on Phase 2b/3 Trial of First-Generation..
DJ
04:11pCureVac Reports Unfavorable Covid-19 Vaccine Study Results Amid High Levels o..
DJ
03:40pCureVac Down 52% After Hours on Interim Covid-19 Vaccine Study Data
DJ
10:37aELANCO ANIMAL HEALTH INCORPORATED  : to Buy Kindred Biosciences for $440 Million..
MT
06/14DGAP-PVR  : Bayer Aktiengesellschaft: Release -2-
DJ
06/14BAYER AKTIENGESELLSCHAFT : Release according to Article 40, Section 1 of the WpH..
EQ
06/13BAYER  : Swiss reject law to help country meet Paris carbon emissions goal
RE
06/13BASF  : Swiss voters look set to reject law to help cut carbon emissions
RE
06/13BASF  : Swiss voters look set to reject law to help cut carbon emissions
RE
06/12BAYER  : Swiss voters to decide on pesticides ban, terrorism law and COVID-19 ai..
RE
06/11EXCLUSIVE : ECB tells Deutsche Bank to find new chairman fast - sources
RE
06/11MARKET CHATTER : Deutsche Bank Facing Increasing Pressure From ECB to Name Chair..
MT
06/10Mexico stalling GMO corn permits ahead of ban, says top farm lobby
RE
06/10Mexico stalling GMO corn permits ahead of ban, says top farm lobby
RE
More news
News in other languages on BAYER AG
04:43pDGAP-NEWS  : CureVac gibt Status-Update zur Phase 2b/3-Studie für Impfstoffkandi..
12:08pEM : Russen mit viel Mühe zum ersten Sieg - 'Haben Job erledigt'
09:35aPRESS1 / ALFRED WIEDER  : Bayerischer Patriot und Vertriebslegende.
06/15MÄRKTE EUROPA/DAX vor Fed-Sitzung weiter freundlich
06/15CUREVAC IM FOKUS : In der Warteschlange für die Impfung
More news
Analyst Recommendations on BAYER AG
More recommendations
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | MarketScreener
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 64,63 €
Last Close Price 53,26 €
Spread / Highest target 59,6%
Spread / Average Target 21,4%
Spread / Lowest Target -51,3%
EPS Revisions
Managers and Directors
NameTitle
Werner Baumann Chairman-Management Board
Wolfgang U. Nickl Chief Financial Officer
Norbert Winkeljohann Chairman-Supervisory Board
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG10.60%63 871
JOHNSON & JOHNSON4.48%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.6.76%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.7.82%204 582